NDANASALSOLUTIONPriority Review
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
DDAVP (desmopressin acetate) by Ferring Pharmaceuticals is clinical pharmacology ddavp tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Approved for nocturia, diabetes insipidus. First approved in 1978.
Drug data last refreshed 21h ago
Mechanism of Action
CLINICAL PHARMACOLOGY DDAVP Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg…
Worked on DDAVP at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.